Hepion Pharmaceuticals (NASDAQ:HEPA), which recently changed its name from ContraVir Pharmaceuticals, is developing targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic...
ContraVir Pharmaceuticals (NASDAQ:CTRV) will present a poster on a Phase 1 single ascending dose study of its drug candidate, CRV431, at the International Liver Congress, taking place in Vienna, Austria from April 10-to...